MSB 3.21% $1.13 mesoblast limited

Cell Therapy News/Articles, page-17789

  1. 2,033 Posts.
    lightbulb Created with Sketch. 724
    This is quite some effort put in here and great European exposure for MSC’s used for aGVHD.

    Who did the trial and who provided the product?

    I am thinking there is definitely a European pharma or two waiting for Mesoblast’s FDA approval in the US to move forward in partnership for aGVHD in the European localities.


 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.